The difference between the targeted drugs moboxetinib and erlotinib

Mobocertinib/Mobocertinib (Mobocertinib) and erlotinib (Erlotinib) are two targeted drugs for tumor treatment, mainly used for the treatment of non-small cell lung cancer (NSCLC). Drug treatment should be carried out according to the recommendations of doctors, and the response between individuals may vary.

1. Targeting effect: Mobosetinib is an EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor that inhibits tumor growth by inhibiting the activity of EGFR mutants. Erlotinib is also an EGFR inhibitor that inhibits the proliferation of tumor cells by interfering with the EGFR signaling pathway.

2. Inhibition spectrum: Mobosetinib has a broad inhibition spectrum and can inhibit a variety of EGFR mutants, including exon 20 insertion mutations of EGFR, which is a type of mutation that is difficult to effectively inhibit by traditional EGFR inhibitors such as erlotinib. Erlotinib mainly acts on EGFR active mutants, such as EGFR exon 19 deletion mutants and EGFR L858R mutants.

3. Resistance: Resistance often occurs after erlotinib treatment, and the most common mechanism is caused byEGFR T790M (submutation). Mobosetinib is a third-generation EGFR inhibitor that has activity against the EGFR T790M mutant and therefore may still be effective in patients who are resistant to erlotinib.

4. Dosage: Mobosetinib is provided in the form of oral capsules. The recommended dose is 160 mg orally once daily. Take mobosetinib at the same time every day with or without food. Erlotinib is available as an oral tablet, and the recommended dose is 150 mg taken orally once daily, on an empty stomach (at least one hour before or two hours after a meal). Until the disease progresses or intolerable toxic side effects occur.

5. Adverse reactions: There are some differences in adverse reactions between these two drugs. Common adverse reactions of moboxetinib include nausea, vomiting, diarrhea, rash, etc. Common adverse reactions of erlotinib include rash, diarrhea, fatigue, etc.

MobosetinibThe original drug is currently on the market in China and has not been included in the medical insurance. Specification40mg*112 pills per box is about 40,000 yuan, which is very expensive.The Hong Kong version of the original drug Specification40mg*30 pills per boxThe price is more than RMB 7,000 (the price may fluctuate due to the exchange rate). Generic drugs of Mobotinib have also been put on the market for sale overseas. The drug ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory40mg*120 pills per boxThe pricemay be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.